Table 1

Demographics and baseline characteristics

CharacteristicPart APart BPart CPart D
DOS+NIR 200 mg
(n=16)
DOS+NIR 300 mg
(n=6)
DOS+C–P
(n=14)
DOS+NIR 200 mg +BEV
(n=6)
DOS+NIR 300 mg +BEV
(n=7)
DOS+C–P+BEV
(n=6)
Age, years
 Median (mean)63.5 (60.9)61.5 (60.5)70.5 (67.6)59.0 (57.0)46.0 (49.4)65.0 (66.8)
 Range39–8540–7941–8237–7435–6660–80
Age group, years, n (%)
 <658 (50.0)3 (50.0)5 (35.7)4 (66.7)6 (85.7)2 (33.3)
 ≥658 (50.0)3 (50.0)9 (64.3)2 (33.3)1 (14.3)4 (66.7)
Body weight, kg
 Mean82.096.681.685.188.680.5
 Range47.7–131.378.3–126.249.9–135.059.9–114.176.4–121.942.3–108.0
Sex, n (%)
 Female9 (56.3)2 (33.3)8 (57.1)4 (66.7)7 (100.0)5 (83.3)
 Male7 (43.8)4 (66.7)6 (42.9)2 (33.3)01 (16.7)
ECOG performance status, n (%)
 08 (50.0)3 (50.0)8 (57.1)2 (33.3)4 (57.1)3 (50.0)
 18 (50.0)3 (50.0)6 (42.9)4 (66.7)3 (42.9)3 (50.0)
Prior regimens
 Median (mean)2.0 (2.2)2.5 (2.3)1.0 (1.6)1.5 (2.7)2.0 (3.0)1.0 (1.3)
Primary tumor site at first diagnosis, n (%)
 Bladder1 (6.3)01 (7.1)000
 Breast3 (18.8)02 (14.3)1 (16.7)2 (28.6)0
 Cholangiocarcinoma00002 (28.6)1 (16.7)
 Colorectal2 (12.5)4 (66.7)1 (7.1)000
 Endometrium1 (6.3)00001 (16.7)
 Gastric1 (6.3)01 (7.1)000
 Gastrointestinal stromal tumor2 (12.5)2 (33.3)01 (16.7)00
 Head and neck1 (6.3)02 (14.3)001 (16.7)
 Liver1 (6.3)1 (16.7)0000
 Lung, small cell003 (21.4)000
 NSCLC1 (6.3)01 (7.1)001 (16.7)
 Ovarian1 (6.3)001 (16.7)1 (14.3)1 (16.7)
 Pancreas1 (6.3)1 (16.7)01 (16.7)00
 Prostate1 (6.3)1 (16.7)1 (7.1)1 (16.7)00
 Other*1 (6.3)02 (14.3)1 (16.7)2 (28.6)1 (16.7)
  • *Other includes appendix, squamous cell carcinoma, vulva, leiomyosarcoma, fallopian tube, uterus, and esophageal cancers.

  • BEV, bevacizumab; C–P, carboplatin–paclitaxel; DOS, dostarlimab; ECOG, Eastern Cooperative Oncology Group; NIR, niraparib; NSCLC, non-small cell lung cancer.